US6908744B1
(en)
*
|
2000-03-14 |
2005-06-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of stimulating cartilage formation
|
ES2394877T3
(es)
*
|
2000-08-14 |
2013-02-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinación homóloga mejorada mediada por proteínas de recombinación de lambda
|
US6586251B2
(en)
*
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
WO2004098490A2
(en)
|
2002-05-17 |
2004-11-18 |
Mount Sinai School Of Medicine Of New York University |
Mesoderm and definitive endoderm cell populations
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
DK2314629T4
(da)
|
2002-07-18 |
2023-02-06 |
Merus Nv |
Rekombinant produktion af blandinger af antistoffer
|
EP1539946A4
(en)
*
|
2002-09-09 |
2006-03-15 |
California Inst Of Techn |
METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
|
WO2004067725A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of identifying modulators of nmur2-mediated activity
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
ES2408582T3
(es)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
CA2583750C
(en)
|
2004-10-19 |
2015-11-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for generating a rodent having a genetic modification
|
US20060117396A1
(en)
*
|
2004-11-30 |
2006-06-01 |
Murphy Andrew J |
Assay methods for identifying modulators of OPSDL3 and transgenic knockouts
|
US20090263900A1
(en)
*
|
2008-04-14 |
2009-10-22 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
PL2125894T3
(pl)
|
2007-03-22 |
2019-08-30 |
Biogen Ma Inc. |
Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania
|
EP3382022A1
(en)
|
2007-06-01 |
2018-10-03 |
Open Monoclonal Technology, Inc. |
Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
|
EP2245155A4
(en)
*
|
2007-12-10 |
2011-05-25 |
Aliva Biopharmaceuticals Inc |
METHODS FOR SEQUENTIALLY REPLACING A TARGETED AREA BY HOMOLOGOUS RECOMBINATION
|
US20090328240A1
(en)
*
|
2008-06-24 |
2009-12-31 |
Sing George L |
Genetically modified mice as predictors of immune response
|
DE102008002715A1
(de)
*
|
2008-06-27 |
2009-12-31 |
Evonik Röhm Gmbh |
2-Hydroxyisobuttersäure produzierende rekombinante Zelle
|
EP3889265A1
(en)
*
|
2008-09-30 |
2021-10-06 |
Ablexis, LLC |
Transgenic mice for the production of chimeric antibodies
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP2564695B1
(en)
|
2009-07-08 |
2015-04-15 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
PT3417701T
(pt)
|
2009-10-06 |
2022-03-16 |
Univ Yale |
Ratinhos modificados geneticamente e enxerto
|
AU2010319894B2
(en)
|
2009-10-29 |
2015-03-05 |
Regeneron Pharmaceuticals, Inc. |
Multifunctional alleles
|
HUE030208T2
(en)
|
2009-12-10 |
2017-04-28 |
Regeneron Pharma |
Heavy-chain antibody-producing mice
|
KR102178064B1
(ko)
|
2009-12-21 |
2020-11-12 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화된 FcγR 마우스
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
EP2501817B2
(en)
*
|
2010-02-08 |
2021-04-21 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
CA3006800C
(en)
|
2010-03-31 |
2022-10-04 |
Ablexis, Llc |
Genetic engineering of non-human animals for the production of chimeric antibodies
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
CN103068993B
(zh)
|
2010-06-22 |
2016-01-06 |
瑞泽恩制药公司 |
杂交轻链小鼠
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
EP2597945B1
(en)
|
2010-07-26 |
2020-07-22 |
Trianni, Inc. |
Transgenic animals and methods of use
|
ES2612459T3
(es)
|
2010-08-02 |
2017-05-17 |
Regeneron Pharmaceuticals, Inc. |
Ratones que producen proteínas de unión que comprenden dominios VL
|
WO2012063048A1
(en)
|
2010-11-08 |
2012-05-18 |
Kymab Limited |
Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
|
ES2634098T3
(es)
|
2011-01-14 |
2017-09-26 |
The Regents Of The University Of California |
Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos.
|
FI3375284T3
(fi)
|
2011-02-15 |
2023-06-15 |
Regeneron Pharma |
Humanisoituja m-csf-hiiriä ja niiden käyttötapoja
|
SG10201913160QA
(en)
|
2011-02-25 |
2020-03-30 |
Regeneron Pharma |
Adam6 mice
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
EP2527842B1
(en)
|
2011-05-12 |
2013-06-05 |
Regeneron Pharmaceuticals, Inc. |
Neuropeptide release assay for sodium channels
|
NZ781020A
(en)
|
2011-08-05 |
2023-01-27 |
Regeneron Pharma |
Humanized universal light chain mice
|
CN106995822B
(zh)
|
2011-09-19 |
2021-06-29 |
科马布有限公司 |
定制供人类使用的抗体、可变结构域和链
|
JP2014531452A
(ja)
|
2011-09-19 |
2014-11-27 |
カイマブ・リミテッド |
動物、レパートリーおよび方法
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
HUE057680T2
(hu)
|
2011-10-17 |
2022-06-28 |
Regeneron Pharma |
Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
ES2651517T3
(es)
|
2011-10-28 |
2018-01-26 |
Regeneron Pharmaceuticals, Inc. |
Ratones con complejo mayor de histocompatibilidad modificado genéticamente
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
RS57893B1
(sr)
|
2011-10-28 |
2019-01-31 |
Regeneron Pharma |
Miševi sa genetski modifikovanim receptorom t ćelija
|
EP4052572A1
(en)
|
2011-10-28 |
2022-09-07 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
|
AU2012332894A1
(en)
|
2011-10-31 |
2014-05-08 |
Merck Sharp & Dohme Corp. |
Nano-suspension process
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
KR102186822B1
(ko)
|
2011-12-20 |
2020-12-04 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 경쇄 마우스
|
CA2863175A1
(en)
|
2012-02-01 |
2013-08-08 |
Regeneron Pharamaceuticals, Inc. |
Humanized rodents that express heavy chains containing vl domains
|
RU2683514C2
(ru)
|
2012-03-06 |
2019-03-28 |
Регенерон Фармасьютикалз, Инк. |
Мышь с общей легкой цепью
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
EP2825035A1
(en)
|
2012-03-16 |
2015-01-21 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
WO2013138712A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
KR102228296B1
(ko)
|
2012-03-16 |
2021-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
JP2015512635A
(ja)
|
2012-03-28 |
2015-04-30 |
カイマブ・リミテッド |
クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
DK2847335T3
(en)
|
2012-04-25 |
2018-08-13 |
Regeneron Pharma |
NUCLEASED MEDIUM TARGETING WITH LARGE TARGET VECTORS
|
RS62121B1
(sr)
|
2012-06-12 |
2021-08-31 |
Regeneron Pharma |
Humanizovane nehumane životinje sa ograničenim lokusima imunoglobulinskog teškog lanca
|
AR091482A1
(es)
*
|
2012-06-21 |
2015-02-04 |
Recombinetics Inc |
Celulas modificadas geneticamente y metodos par su obtencion
|
KR102355959B1
(ko)
|
2012-08-23 |
2022-01-27 |
어젠시스 인코포레이티드 |
158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
KR102134088B1
(ko)
|
2012-08-24 |
2020-07-14 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
|
UA118090C2
(uk)
*
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
KR102340059B1
(ko)
|
2012-09-07 |
2021-12-17 |
예일 유니버시티 |
유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
|
ES2748662T3
(es)
|
2012-11-05 |
2020-03-17 |
Institute For Res In Biomedicine Irb |
Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
|
EP2958938B1
(en)
|
2013-02-20 |
2019-04-17 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized t-cell co-receptors
|
SG10201706741VA
(en)
|
2013-02-20 |
2017-10-30 |
Regeneron Pharma |
Genetic modification of rats
|
BR112015019350A2
(pt)
|
2013-02-20 |
2017-08-22 |
Regeneron Pharma |
Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
CA2900824A1
(en)
|
2013-02-22 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized major histocompatibility complex
|
CN108464278B
(zh)
|
2013-03-11 |
2021-05-04 |
瑞泽恩制药公司 |
表达嵌合的主要组织相容性复合物(mhc)ii类分子的转基因小鼠
|
CN105188358B
(zh)
|
2013-03-11 |
2018-01-26 |
瑞泽恩制药公司 |
表达嵌合的主要组织相容性复合物(mhc)i类分子的转基因小鼠
|
JP2016519568A
(ja)
|
2013-03-13 |
2016-07-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
共通軽鎖のマウス
|
TR201901668T4
(tr)
|
2013-03-13 |
2019-02-21 |
Regeneron Pharma |
Sınırlı bir immünoglobulin hafif zincir repertuvarını eksprese eden fareler.
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
PL3456831T3
(pl)
*
|
2013-04-16 |
2021-12-06 |
Regeneron Pharmaceuticals, Inc. |
Ukierunkowana modyfikacja genomu szczura
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
TWI646108B
(zh)
|
2013-08-01 |
2019-01-01 |
艾澤西公司 |
結合至cd37蛋白質之抗體藥物結合物(adc)
|
JP6998656B2
(ja)
|
2013-08-07 |
2022-02-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
lincRNA欠失非ヒト動物
|
HUE044747T2
(hu)
|
2013-09-18 |
2019-11-28 |
Regeneron Pharma |
Hisztidinmódosított könnyûláncú antitestek és genetikailag módosított nem humán állati élõlények ugyanennek az elõállítására
|
SI3175706T1
(sl)
|
2013-09-23 |
2019-03-29 |
Regeneron Pharmaceuticals, Inc. |
Nehumane živali s humaniziranim genom signal-regulatornega proteina
|
NL2013554B1
(en)
|
2013-10-01 |
2016-01-08 |
Kymab Ltd |
Animal models and therapeutic molecules.
|
WO2015077071A1
(en)
|
2013-11-19 |
2015-05-28 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized b-cell activating factor gene
|
AU2014353347B2
(en)
|
2013-11-19 |
2020-07-02 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized a proliferation-inducing ligand gene
|
RU2685914C1
(ru)
|
2013-12-11 |
2019-04-23 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
EP3080279B1
(en)
|
2013-12-11 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
JP6593595B2
(ja)
|
2014-01-15 |
2019-10-23 |
正道 山本 |
Atp可視化動物およびその用途
|
SG11201607015VA
(en)
|
2014-03-21 |
2016-09-29 |
Regeneron Pharma |
V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
|
SG11201607203XA
(en)
|
2014-03-21 |
2016-09-29 |
Regeneron Pharma |
Non-human animals that make single domain binding proteins
|
FI3841877T3
(fi)
|
2014-05-19 |
2023-12-01 |
Regeneron Pharma |
Ihmisen epo:a ilmentäviä geneettisesti muunneltuja hiiriä
|
ES2877275T3
(es)
|
2014-05-30 |
2021-11-16 |
Regeneron Pharma |
Animales con dipeptidil peptidasa IV (DPP4) humanizada
|
KR102374379B1
(ko)
|
2014-06-06 |
2022-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
표적화된 좌를 변형시키는 방법 및 조성물
|
PT3157956T
(pt)
*
|
2014-06-19 |
2020-04-09 |
Regeneron Pharma |
Animais não humanos com um gene 1 de morte programada humanizada em células
|
HUE049405T2
(hu)
|
2014-06-23 |
2020-09-28 |
Regeneron Pharma |
Nukleáz-közvetített DNS-összeállítás
|
PT3161128T
(pt)
|
2014-06-26 |
2018-11-21 |
Regeneron Pharma |
Métodos e composições para modificações genéticas alvejadas e métodos de utilização
|
SG11201701040XA
(en)
|
2014-09-19 |
2017-03-30 |
Regeneron Pharma |
Chimeric antigen receptors
|
AU2015332451A1
(en)
|
2014-10-15 |
2017-04-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
PL3221457T3
(pl)
*
|
2014-11-21 |
2019-09-30 |
Regeneron Pharmaceuticals, Inc. |
Sposoby i kompozycje do celowanej modyfikacji genetycznej z zastosowaniem sparowanych przewodników RNA
|
RS61080B1
(sr)
|
2014-11-24 |
2020-12-31 |
Regeneron Pharma |
Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
|
HUE043132T2
(hu)
|
2014-12-05 |
2019-07-29 |
Regeneron Pharma |
Nem-humán állatok, amelyek egy humanizált differenciáció klaszter 47 gént tartalmazzák
|
MX2017007636A
(es)
|
2014-12-09 |
2018-03-28 |
Regeneron Pharma |
Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
|
WO2016100819A1
(en)
*
|
2014-12-19 |
2016-06-23 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
MX2017011380A
(es)
|
2015-03-09 |
2018-04-26 |
Agensys Inc |
Conjugados anticuerpo-farmaco (adc) que se ligan a proteinas flt3.
|
SG11201706809WA
(en)
|
2015-03-16 |
2017-09-28 |
Regeneron Pharma |
Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
|
AU2016232715A1
(en)
|
2015-03-19 |
2017-09-28 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
CN113349159B
(zh)
|
2015-04-06 |
2022-11-11 |
瑞泽恩制药公司 |
非人动物中的人源化t细胞介导的免疫应答
|
CN113424798B
(zh)
|
2015-04-13 |
2023-01-13 |
再生元制药公司 |
人源化SIRPα-IL15敲入小鼠及其使用方法
|
US10395759B2
(en)
|
2015-05-18 |
2019-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for copy number variant detection
|
BR112017025507A2
(pt)
|
2015-05-29 |
2018-08-07 |
Regeneron Pharmaceuticals, Inc. |
roedor, célula isolada de roedor ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para preparação de um roedor e para identificação de um candidato terapêutico.
|
JP2018526005A
(ja)
|
2015-09-02 |
2018-09-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
前立腺がんのげっ歯類モデル
|
RU2745403C2
(ru)
|
2015-11-20 |
2021-03-24 |
Регенерон Фармасьютикалз, Инк. |
Животные, отличные от человека, имеющие гуманизированный ген активации лимфоцитов-3
|
DE102016122317A1
(de)
*
|
2015-11-24 |
2017-05-24 |
Glaxosmithkline Intellectual Property Development Limited |
Transientes transfektionsverfahren für retrovirale produktion
|
ES2939617T3
(es)
*
|
2015-11-24 |
2023-04-25 |
Glaxosmithkline Ip Dev Ltd |
Líneas celulares estables para producción retroviral
|
WO2017095939A1
(en)
|
2015-12-03 |
2017-06-08 |
Trianni, Inc. |
Enhanced immunoglobulin diversity
|
MX2018008701A
(es)
|
2016-01-13 |
2019-06-06 |
Regeneron Pharma |
Roedores que tienen una region de diversidad de cadena pesada modificada geneticamente.
|
US20170218398A1
(en)
*
|
2016-01-30 |
2017-08-03 |
Markus Alexander Brown |
Method to selectively target cancerous cells for genetic manipulation
|
IL260743B2
(en)
|
2016-02-04 |
2024-03-01 |
Trianni Inc |
Advanced production of antibodies
|
WO2017136712A1
(en)
*
|
2016-02-04 |
2017-08-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered angptl8 gene
|
KR20180110107A
(ko)
|
2016-02-16 |
2018-10-08 |
리제너론 파마슈티칼스 인코포레이티드 |
돌연변이 키뉴레니나아제 유전자를 갖는 비인간 동물
|
CN109068621B
(zh)
|
2016-02-29 |
2021-07-20 |
再生元制药公司 |
具有人源化的tmprss基因的啮齿类动物
|
WO2017172958A1
(en)
|
2016-03-29 |
2017-10-05 |
Regeneron Pharmaceuticals, Inc. |
Genetic variant-phenotype analysis system and methods of use
|
EP4368637A2
(en)
|
2016-05-20 |
2024-05-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide rnas
|
CN109640644B
(zh)
|
2016-06-03 |
2021-10-26 |
瑞泽恩制药公司 |
表达外源末端脱氧核苷酸转移酶的非人动物
|
IL299099A
(en)
|
2016-06-27 |
2023-02-01 |
Univ California |
Combinations of cancer treatments
|
WO2018001241A1
(zh)
|
2016-06-28 |
2018-01-04 |
北京百奥赛图基因生物技术有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
MX2019001211A
(es)
|
2016-07-29 |
2019-09-16 |
Regeneron Pharma |
Ratones que comprenden mutaciones que dan lugar a la expresión de la fibrilina-1 truncada en c.
|
SG10202102997UA
(en)
*
|
2016-09-30 |
2021-04-29 |
Regeneron Pharma |
Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus
|
SG11201903344XA
(en)
|
2016-11-04 |
2019-05-30 |
Regeneron Pharma |
Non-human animals having an engineered immunoglobulin lambda light chain locus
|
US11064685B2
(en)
|
2017-02-27 |
2021-07-20 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal models of retinoschisis
|
SG11201912236YA
(en)
|
2017-07-31 |
2020-01-30 |
Regeneron Pharma |
Crispr reporter non-human animals and uses thereof
|
JP7359753B2
(ja)
|
2017-07-31 |
2023-10-11 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Casトランスジェニックマウスの胚性幹細胞およびマウスならびにその使用
|
PT3687287T
(pt)
|
2017-09-29 |
2023-11-03 |
Regeneron Pharma |
Roedores que expressam complexo c1q humanizado
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
CN109666701B
(zh)
*
|
2017-10-13 |
2021-08-24 |
百奥赛图(北京)医药科技股份有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
EP3585164B1
(en)
|
2017-11-30 |
2023-12-27 |
Regeneron Pharmaceuticals, Inc. |
Rats comprising a humanized trkb locus
|
CA3084049A1
(en)
|
2017-12-05 |
2019-06-13 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
|
CA3089331A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
MA52177A
(fr)
|
2018-03-26 |
2021-02-17 |
Regeneron Pharma |
Rongeurs humanisés pour tester des agents thérapeutiques
|
EP3811364A1
(en)
|
2018-06-01 |
2021-04-28 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for sparse vector-based matrix transformations
|
CA3103646C
(en)
|
2018-06-14 |
2023-06-27 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals capable of engineered dh-dh rearrangement and uses thereof
|
AU2019308205A1
(en)
|
2018-07-16 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal models of DITRA disease and uses thereof
|
CN109504708A
(zh)
*
|
2018-12-03 |
2019-03-22 |
江苏集萃药康生物科技有限公司 |
一种筛选标记自我删除的基因打靶载体及方法
|
CN116064550A
(zh)
|
2018-12-20 |
2023-05-05 |
瑞泽恩制药公司 |
核酸酶介导的重复扩增
|
US20220104468A1
(en)
|
2019-01-22 |
2022-04-07 |
St. Jude Children's Research Hospital |
Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
|
JP2022521358A
(ja)
|
2019-02-18 |
2022-04-06 |
バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド |
ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
|
US11464217B2
(en)
|
2019-02-22 |
2022-10-11 |
Regeneron Pharmaceuticals, Inc. |
Rodents having genetically modified sodium channels and methods of use thereof
|
US11111504B2
(en)
|
2019-04-04 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
AU2020253532A1
(en)
|
2019-04-04 |
2021-09-02 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
US11136353B2
(en)
|
2019-04-15 |
2021-10-05 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
|
KR20220016869A
(ko)
|
2019-06-04 |
2022-02-10 |
리제너론 파마슈티칼스 인코포레이티드 |
베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
|
BR112021023683A2
(pt)
|
2019-06-05 |
2022-02-01 |
Regeneron Pharma |
Roedor e camundongo geneticamente modificado, embrião de roedor, célula b do roedor ou camundongo geneticamente modificado, hibridoma, população de células b, célula-tronco embrionária, célula de mamífero, métodos de produção de um anticorpo, de uma cadeia pesada, de um domínio variável, de uma coleção de domínios variáveis, de uma cadeia leve, de uma sequência nucleotídica, de um roedor geneticamente modificado e de células es, de geração de um domínio variável e in vitro para gerar uma célula recombinante de roedor, e, vetor de direcionamento
|
JP2022534560A
(ja)
|
2019-06-07 |
2022-08-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化アルブミン遺伝子座を含む非ヒト動物
|
CN114008193A
(zh)
|
2019-06-27 |
2022-02-01 |
瑞泽恩制药公司 |
Tdp-43蛋白病的建模
|
MX2022000133A
(es)
|
2019-07-01 |
2022-04-27 |
Tonix Pharma Ltd |
Anticuerpos anti-cd154 y usos de los mismos.
|
JP2022550434A
(ja)
|
2019-10-04 |
2022-12-01 |
ティーエーイー ライフ サイエンシーズ |
Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
AU2021212668A1
(en)
|
2020-01-28 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized PNPLA3 locus and methods of use
|
US20230081547A1
(en)
|
2020-02-07 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized klkb1 locus and methods of use
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
JP2023523174A
(ja)
|
2020-04-21 |
2023-06-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化cxcl13遺伝子を有する非ヒト動物
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
CN115988960A
(zh)
|
2020-06-25 |
2023-04-18 |
株式会社湖美宝 |
杂合转基因动物
|
KR20230066386A
(ko)
|
2020-09-11 |
2023-05-15 |
리제너론 파마슈티칼스 인코포레이티드 |
항원 특이적 항체의 확인 및 제조
|
CA3191836A1
(en)
|
2020-10-01 |
2022-04-07 |
Andrew J. Murphy |
Rodent animals expressing human cr1
|
CN116848254A
(zh)
|
2020-12-16 |
2023-10-03 |
瑞泽恩制药公司 |
表达人源化Fcα受体的小鼠
|
KR20230124973A
(ko)
|
2020-12-21 |
2023-08-28 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 tslp 유전자, 인간화 tslp 수용체 유전자, 및/또는인간화 il7ra 유전자를 갖는 비인간 동물
|
WO2022140219A1
(en)
|
2020-12-23 |
2022-06-30 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
US20240059781A1
(en)
|
2021-01-06 |
2024-02-22 |
Tonix Pharma Limited |
Methods of inducing immune tolerance with modified anti-cd154 antibodies
|
CA3213460A1
(en)
|
2021-03-31 |
2022-10-06 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrb repertoire
|
WO2022220603A1
(ko)
|
2021-04-16 |
2022-10-20 |
고려대학교 산학협력단 |
코로나-19 바이러스 표적 인간 항체
|
CA3221878A1
(en)
|
2021-06-18 |
2022-12-22 |
David Stover |
Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof
|
WO2023077053A2
(en)
|
2021-10-28 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
WO2023122506A1
(en)
|
2021-12-20 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
WO2023154861A1
(en)
|
2022-02-11 |
2023-08-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for screening 4r tau targeting agents
|
WO2023212560A1
(en)
|
2022-04-26 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
A rodent model of fibrodysplasia ossificans progressiva
|
WO2023235677A1
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
US20230417899A1
(en)
|
2022-06-27 |
2023-12-28 |
Oshkosh Corporation |
Position tracking for a lift device
|
US20240102045A1
(en)
|
2022-07-19 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
US20240099279A1
(en)
|
2022-09-22 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice expressing components of human cellular immune system
|
US20240130341A1
(en)
|
2022-09-29 |
2024-04-25 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|